February 28, 2010

By all accounts, it’s been a very busy first half of the season for cough-cold manufacturers, even though the 52-week comparable period is only showing a 1.9% lift in overall sales across food, drug and mass (minus Walmart) for the period ended Jan. 24, according to Information Resources Inc. data. For the 2009-2010 season, the weekly percentage of outpatient visits for influenza-like illness peaked at the end of October 2009 at 7.7%, the Centers for Disease Control and Prevention reported. That peak was higher than the three previous influenza seasons as reported by the U.S. Outpatient ILI Surveillance Network.

February 24, 2010

Quigley Corp. on Wednesday announced the introduction of series of online videos aimed at educating...

February 4, 2010

Not even the threat of an H1N1 flu pandemic could shake today’s recession-minded employee from...

January 20, 2010

Healthy Advice Networks, a provider of physician office-based, patient-education programs, earlier this week announced a...

January 10, 2010

All of the awareness driven around H1N1 certainly has created plenty of activity in the...

December 20, 2009

Consumers can be expected to self-identify a cough, and even locate a cough remedy in...

July 30, 2009

Today’s novel H1N1 news scare may very well turn out to be a “boy who...

February 28, 2009

Despite all the debate over the use of cough-cold medicines in children under the age of 12, sales of cough-cold medicines didn’t do too badly last year. For the 52 weeks ended Jan. 25, sales of all cough-cold remedies — including cough drops, cough syrups, cold-allergy liquids and cold-allergy tablets — were up 10.5%, totaling $4 billion across food, drug and mass outlets (minus Walmart) according to Information Resources Inc data. Of course, the lion’s share of that growth comes courtesy of the latest allergy reliever to make its way from prescription vials to over-the-counter aisles. Factoring out the sales impact of McNeil Consumer Healthcare’s Zyrtec, which generated in excess of $331 million across its Zyrtec syrup, Zyrtec tablet and Zyrtec-D tablet, the overall cough-cold category still grew by 1.4%. Considering that’s on a base of $3.6 billion, that represents incremental growth of almost $50 million.

February 1, 2008

When retailers and suppliers gather at the Cough, Cold and Allergy Show on March 2 at the Hilton Sandestin Beach Golf Resort and Spa in Destin, Fla., they will be discussing a variety of issues, including the impact of the FDA's recommendation against the use of cough-cold medicines for children under 2 years of age.

November 14, 2007

What are consumers saying about the FDA's recent recommendation against OTC cough-cold products in children under 6 years old? Will it change their purchasing habits? What will they do now? With cold-and-flu season just around the corner, Drug Store News.TV went out on the streets of New York City to find out.

October 17, 2007

Four physicians, including Michael Shannon, professor of pediatrics at Harvard Medical School, and Daniel Levy,...

February 28, 2007

The most significant event that occurred during a soft 2006-2007 cough-and-cold season was the shift of the decongestant pseudoephedrine behind the counter in all 50 states. To be sure, some states still require more strict regulations on the sale of PSE, but at least now PSE is behind the counter in a legislative effort to thwart homegrown methamphetamine makers.